-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 14, 2021, Pfizer announced that the U.
AS is a chronic inflammatory disease with symptoms usually occurring before the age of 30
Tofacitinib is a JAK inhibitor developed by Pfizer, which can effectively inhibit the activity of JAK1 and JAK3 and block the signaling of various inflammatory cytokines
The approval is based on positive data from a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial
Note: The original text has been deleted
References:
[1] US FDA Approves Pfizer's XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis.